Catalog No.
Product Name
Application
Product Information
Citations
-
FLT3 Inhibitor
FLT3-IN-16 is a highly effective FLT3 inhibitor, exhibiting an IC50 value of 1.1 μM. This compound plays a critical role in the study of acute myeloid leukemia (AML), facilitating research into therapeutic strategies targeting FLT3 signaling pathways. FLT3-IN-16 is essential for investigating the molecular mechanisms underlying AML and evaluating the efficacy of FLT3-targeted treatments. -
FLT3 Inhibitor
FLT3-IN-10 is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), a key regulator in hematopoiesis and a pivotal target in certain leukemias. This compound exhibits significant activity against FLT3-mutated acute myeloid leukemia (AML), making it a valuable tool for research into targeted therapies. Its application in preclinical studies can aid in the understanding of FLT3's role in oncogenesis and in evaluating potential therapeutic strategies for FLT3-driven malignancies. -
FLT3/CDK5 Inhibitor
AMG 925 (HCl) is a potent dual inhibitor targeting FLT3 and CDK5, demonstrating IC50 values of 2±1 nM and 3±1 nM, respectively. This compound exhibits selectivity for these kinases, making it a valuable tool for research into hematological malignancies and cancer progression. Its oral bioavailability further enhances its utility in preclinical studies investigating therapeutic interventions for FLT3-driven malignancies and CDK5-associated diseases. -
FLT3 Inhibitor
FLT3-IN-19 is a potent and selective inhibitor of the FLT3 receptor tyrosine kinase, exhibiting an IC50 of 0.213 nM. This compound is primarily utilized in the research of acute myeloid leukemia (AML), facilitating studies on FLT3-dependent signaling pathways and potential therapeutic interventions. Its high specificity makes it an invaluable tool for understanding the molecular mechanisms underlying FLT3-driven malignancies. -
FLT3/Haspin Inhibitor
HSK205 is a potent dual inhibitor of FLT3 and Haspin, exhibiting an IC50 of 0.187 nM for FLT3. This compound demonstrates significant antitumor activity, making it a valuable tool in cancer research. Its dual targeting provides insights into the therapeutic potential for FLT3-driven malignancies and the role of Haspin in cell cycle regulation. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-3 is a highly effective inhibitor of PDGFRα and FLT3, exhibiting IC50 values of 0.153 μM and 0.004 μM, respectively. This compound serves as a valuable tool in the investigation of acute myeloid leukemia and chronic eosinophilic leukemia. Its potent inhibitory activity against key receptors makes it a significant candidate for related biomedical research applications. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-3 is a highly selective inhibitor targeting FLT3 internal tandem duplications (FLT3-ITD), demonstrating potent activity with IC50 values of 0.3 nM for FLT3D835Y, 0.4 nM for FLT3, and 0.9 nM for FLT3-ITD. This compound effectively inhibits FLT3 phosphorylation and exhibits significant antiproliferative effects against acute myeloid leukemia cell lines. It serves as a valuable tool in research aimed at understanding and developing therapies for FLT3-ITD associated malignancies. -
FLT3/IRAK4 Inhibitor
Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor that demonstrates significant antitumor activity. It is particularly relevant for research involving myeloid leukemia, where it may offer insights into therapeutic strategies targeting these pathways. Its unique mechanism of action makes it a valuable tool for investigating the roles of FLT3 and IRAK4 in cancer biology. -
PROTAC FLT3-ITD Degrader
PF15 is a PROTAC designed to target FLT3 kinase through its ligands linked with CRBN. This highly selective FLT3-ITD degrader exhibits a DC50 of 76.7 nM, effectively inhibiting the proliferation of FLT3-ITD-positive cells. PF15 down-regulates the phosphorylation of FLT3 and STAT5, demonstrating significant anti-tumor activity in mouse models, making it a valuable tool for leukemia research. -
Flt3 Inhibitor
D-65476 is a selective inhibitor of the Flt3 receptor tyrosine kinase, primarily acting in the absence of IL-3. It effectively suppresses the proliferation of TEL-Flt3 transfected BA/F3 cells, demonstrating an IC50 value of 0.2 μM. This compound is a valuable tool for exploring Flt3-driven leukemias and related therapeutic strategies. -
FLT3 Inhibitor
LT-850-166 is a potent inhibitor of FLT3, a receptor tyrosine kinase involved in hematopoiesis and leukemogenesis. It effectively targets various FLT3 mutations, demonstrating significant potential in the treatment of acute myeloid leukemia (AML) and other FLT3-driven malignancies. This compound serves as a valuable tool for research applications focused on understanding FLT3 signaling pathways and the development of targeted cancer therapies. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-2 is a selective inhibitor of FLT3 internal tandem duplications (FLT3-ITD), exhibiting IC50 values of 0.3 nM for FLT3D835Y, 0.4 nM for FLT3, and 1.0 nM for FLT3-ITD. This compound effectively blocks FLT3 phosphorylation and demonstrates robust antiproliferative effects on acute myeloid leukemia cell lines. It is a valuable tool for research into targeted therapies for leukemia and related disorders. -
FLT3/ITD Mutation Inhibitor
HP1328 is a potent inhibitor of the FLT3 receptor tyrosine kinase specifically targeting the FLT3/ITD mutation. This benzoimidazole scaffold-based compound demonstrates significant efficacy in reducing leukemia burden and prolonging survival in murine models of FLT3/ITD leukemia. HP1328 is valuable for research focused on targeted therapies for acute myeloid leukemia and advancing understanding of FLT3-related pathophysiology. -
FLT3 Inhibitor
FLT3-IN-11 is a potent and selective inhibitor of FLT3 kinase, exhibiting IC50 values of 7.22 nM and 4.95 nM for wild-type FLT3 and the FLT3-D835Y mutant, respectively. This compound demonstrates over 1000-fold selectivity for FLT3 compared to c-KIT. FLT3-IN-11 shows significant anti-acute myeloid leukemia (AML) activity, with an IC50 of 3.2 nM in MV4-11 cell assays, making it a valuable tool for research in AML therapeutics. -
FLT3 Inhibitor
FLT3-IN-32 TFA is a selective inhibitor of FLT3, targeting both FLT3-ITD and FLT3-D835Y with IC50 values of 2.40 nM and 3.83 nM, respectively. This compound effectively inhibits the proliferation and survival of human MV4-11 cells, demonstrating an IC50 of 0.07 nM. FLT3-IN-32 TFA is valuable for research focused on acute myeloid leukemia (AML), providing insights into targeted therapeutic strategies. -
FLT3 Inhibitor
MolPort-002-705-878 is a selective inhibitor of FMS-like tyrosine kinase 3 (FLT3) with a binding affinity of -11.33 kcal/mol. It effectively inhibits the proliferation of FLT3-mutated acute myeloid leukemia (AML) cells, making it a valuable tool for research in this domain. This compound holds potential for advancing studies focused on FLT3-mutated AML therapies. -
FLT3 Inhibitor
LT-540-717 is a potent inhibitor of the FLT3 receptor, exhibiting an IC50 of 0.62 nM. It demonstrates significant antiproliferative activity against cells harboring various acquired FLT3 mutations, including FLT3 ITD, D835V, F691L, and D835Y. Due to its selective inhibition of FLT3, LT-540-717 is a valuable candidate for research focused on acute myeloid leukemia (AML) treatment strategies. -
Mer/Flt3 Tyrosine Kinase Inhibitor
UNC1666 is an ATP-competitive dual-target inhibitor of the Mer and Flt3 tyrosine kinases, exhibiting potent inhibition with IC50 values of 0.55 nM and 0.69 nM, and Ki values of 0.16 nM and 0.67 nM, respectively. This compound effectively inhibits the kinase activities of Mer and Flt3, leading to decreased phosphorylation levels and suppression of downstream pro-survival signaling pathways such as Erk1/2, Akt, and Stat. Additionally, UNC1666 promotes apoptosis and reduces colony formation in acute myeloid leukemia cells, making it a valuable tool for research focused on this malignancy. -
FLT3/FLT3-ITD Inhibitor
FLT3/ITD-IN-5 is a potent inhibitor of FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is designed for use in cancer research, providing valuable insights into therapies targeting FLT3 mutations commonly found in acute myeloid leukemia (AML). Its high selectivity makes it an essential tool for studying FLT3 signaling pathways and developing targeted treatments. -
FLT3-ITD Inhibitor
FLT3/ITD-IN-4 is a selective inhibitor of FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD), exhibiting an IC50 of 2.3 nM. This compound demonstrates potent biological activity against FLT3-ITD mutations, making it valuable for research in acute myeloid leukemia. FLT3/ITD-IN-4 is ideal for studies exploring targeted therapies and the underlying mechanisms of FLT3-mediated signaling. -
FLT3 Receptor Antagonist
BDT001 is a selective FLT3 receptor antagonist that inhibits the signaling pathways associated with FLT3 activation. This compound demonstrates significant potential in research applications focused on pain disorders, cancer, and autoimmune diseases by modulating the activity of FLT3, a receptor implicated in cellular proliferation and survival. BDT001 serves as a valuable tool for investigating therapeutic strategies targeting FLT3-related pathologies. -
BTK/FLT3 Inhibitor
RSH-7 is a potent inhibitor of Bruton's tyrosine kinase (BTK) and Fms-like tyrosine kinase 3 (FLT3), exhibiting IC50 values of 47 nM and 12 nM, respectively. This compound induces apoptosis and demonstrates significant antiproliferative activity. By inhibiting BTK and FLT3 signaling pathways, RSH-7 is a valuable tool for research in oncology and targeted therapies for hematological malignancies. -
FLT3 Inhibitor
FLT3-IN-26 is a potent FLT3 inhibitor with a pIC50 value of 7.367. This compound demonstrates significant biological activity against FLT3, making it a valuable tool for investigating acute myeloid leukemia. Its specificity and efficacy facilitate research into targeted therapies for this malignancy. -
FLT3 Inhibitor
FLT3-IN-12 is a selective and orally bioavailable inhibitor of the FLT3 kinase, demonstrating IC50 values of 1.48 nM for FLT3-WT and 2.87 nM for the FLT3-D835Y mutant. This compound exhibits exceptional selectivity over c-KIT, surpassing 1000-fold. Additionally, FLT3-IN-12 showcases potent anti-acute myeloid leukemia (AML) activity, with an IC50 of 0.75 nM against the MV4-11 cell line, making it a valuable tool for the study of FLT3-driven malignancies and potential therapeutic applications in AML. -
FLT3 Inhibitor
FLT3-IN-15 is a potent and orally bioavailable inhibitor of the FLT3 receptor, exhibiting IC50 values of 0.87 nM for FLT3 and 0.32 nM for the FLT3/D835Y mutant. This compound is primarily utilized in research related to acute myeloid leukemia, providing insights into the therapeutic potential of targeting aberrant FLT3 signaling pathways in cancer treatment. -
FLT3 inhibitor
FLT3-IN-23 is a potent inhibitor of the Fms-like tyrosine kinase 3 (FLT3), exhibiting an IC50 value of 7.42 nM. It demonstrates significant antiproliferative activity against BaF3 cells harboring multiple FLT3 tyrosine kinase domain (TKD) and internal tandem duplication (ITD) mutations. This compound serves as a valuable tool for research in targeted therapies for FLT3-mutant leukemias. -
TRK Inhibitor
TRK II-IN-1 is a selective type II TRK inhibitor, exhibiting IC50 values of 3.3, 6.4, 4.3, and 9.4 nM against TRKA, TRKB, TRKC, and the TRKAG667C mutant, respectively. Additionally, it demonstrates inhibitory activity against FLT3, RET, and VEGFR2 with IC50 values of 1.3, 9.9, and 71.1 nM, respectively. This compound is valuable for research into TRK-driven cancers and related signaling pathways. -
FLT3/D835Y Inhibitor
FLT3/D835Y-IN-1 is a potent and selective inhibitor targeting FLT3 and the FLT3/D835Y mutant with IC50 values of 0.26 nM and 0.18 nM, respectively. This orally active compound demonstrates significant inhibition of tumor growth and exhibits anticancer efficacy, making it a valuable tool for research into acute myeloid leukemia (AML). FLT3/D835Y-IN-1 provides a targeted approach for studying the effects of FLT3 mutations in cellular and animal models of AML. -
FLT3 Inhibitor
CHEMBL4444839 is a potent FLT3 inhibitor that plays a crucial role in the study of acute myeloid leukemia (AML). Its ability to selectively target FLT3 makes it a valuable tool for investigating the molecular mechanisms of AML and developing potential therapeutic strategies. Researchers can leverage CHEMBL4444839 to explore the effects of FLT3 inhibition on cell proliferation and survival in AML models. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-1 is a selective inhibitor of the platelet-derived growth factor receptor alpha (PDGFRα) and the Fms-like tyrosine kinase 3 (FLT3), demonstrating IC50 values of 0.036 μM and 0.003 μM, respectively. This compound is particularly relevant for investigations into acute myeloid leukemia (AML) and chronic eosinophilic leukemia (CEL), providing a valuable tool for exploring therapeutic strategies targeting these malignancies. Researchers utilizing PDGFRα/FLT3-ITD-IN-1 can gain insights into the molecular mechanisms underlying these hematological disorders. -
FLT3 Inhibitor
FLT3-IN-18 is a highly selective inhibitor of FLT3, exhibiting an IC50 value of 0.003 μM. This compound effectively induces apoptosis and enforces G1 phase cell cycle arrest in FLT3-positive cells. Additionally, FLT3-IN-18 inhibits both FLT3 and STAT5 phosphorylation, making it a valuable tool for investigating the signaling pathways involved in acute myeloid leukemia (AML). Its potency and specificity position FLT3-IN-18 as a crucial reagent for researching FLT3-driven malignancies. -
FLT3 Inhibitor
TTT 3002 is a potent FLT3 inhibitor that effectively targets FLT3 phosphorylation in the presence of activating mutations at residue D835, demonstrating an IC50 of 0.2 nM. This compound is valuable for research in acute myeloid leukemia (AML) and other related hematologic malignancies. Its specificity and efficacy make it a crucial tool for investigating FLT3 signaling pathways and developing targeted therapies. -
FLT3/ITD Mutation Inhibitor
HP1142 is a selective inhibitor of the FLT3 receptor tyrosine kinase, specifically targeting the FLT3/ITD mutation. This compound, derived from a benzoimidazole scaffold, demonstrates significant efficacy in inhibiting FLT3 signaling pathways. HP1142 is primarily utilized in research focused on FLT3/ITD mutated leukemia, providing valuable insights into therapeutic strategies for this malignancy. -
FLT3/CDK4 Inhibitor
FLT3/CDK4-IN-1 is a highly selective, orally active dual inhibitor targeting FLT3 and CDK4, demonstrating IC50 values of 11 nM and 7 nM, respectively. This compound exhibits significant antiproliferative activity against specific cancer cell lines and shows promising antitumor effects in vivo. FLT3/CDK4-IN-1 is suitable for research applications focused on cancer biology, particularly in exploring pathways associated with leukemias and solid tumors. -
PDGFRα/FLT3 Inhibitor
PDGFRα/FLT3-ITD-IN-2 is a selective inhibitor targeting PDGFRα and FLT3, exhibiting IC50 values greater than 20 μM and 1.654 μM, respectively. This compound demonstrates significant biological activity relevant to the treatment of acute myeloid leukemia and chronic eosinophilic leukemia. Its efficacy in modulating these pathways makes it a valuable tool for investigational research in cancer therapeutics. -
PDGFR/TEL-PDGFR/FLT3/KIT Inhibitor
AGL 2043 is a potent inhibitor of PDGFR, TEL-PDGFR, FLT3, and KIT kinases, exhibiting an IC50 value of 0.8 μM against PDGFR. This compound demonstrates significant biological activity by effectively reducing porcine cardiac smooth muscle cell proliferation and mitigating balloon-induced vascular stenosis. AGL 2043 presents promising applications in the development of anti-restenotic and anticancer therapies. -
FLT3/IRAK1/4 Inhibitor
NCGC1481 is a potent inhibitor of FLT3, IRAK1, and IRAK4, displaying IC50 values of <0.5 nM, 22.6 nM, and 0.8 nM, respectively. This compound effectively mitigates the adaptive resistance of leukemia cells to FLT3 inhibitors, demonstrating significant antileukemic activity. NCGC1481 is suitable for research focused on leukemia treatment and the modulation of key signaling pathways involved in cancer cell survival and proliferation. -
FLT3 Inhibitor
Flt-3 Inhibitor III is a selective inhibitor of the FLT3 kinase with a potent IC50 value of 50 nM. This compound demonstrates minimal activity against other kinases, thereby ensuring specificity. Flt-3 Inhibitor III is primarily utilized in research applications related to cancer biology, particularly in studies investigating FLT3 mutations in acute myeloid leukemia (AML). Its ability to inhibit FLT3 activity underscores its potential as a therapeutic agent in targeted cancer therapies. -
MERTK/FLT3 Inhibitor
MRX-2843 hydrochloride is an orally active, ATP-competitive inhibitor targeting MERTK and FLT3 tyrosine kinases. It demonstrates potent enzymatic inhibitory activity with IC50 values of 1.3 nM for MERTK and 0.64 nM for FLT3. This compound is ideal for research applications investigating cancer therapies and related signaling pathways involving these kinases. -
FLT3 Inhibitor
AAE871 is a potent type I FLT3 inhibitor, exhibiting an IC50 value of 0.034 µM. It demonstrates significant biological activity in inhibiting FLT3 signaling, making it a valuable tool for investigating acute myeloid leukemia (AML) and related hematological malignancies. AAE871 is useful in preclinical studies aimed at understanding FLT3-mediated pathways and their role in cancer progression. -
FLT3 Inhibitor
FLT3-IN-38 is a selective FLT3 inhibitor that targets the FLT3 receptor tyrosine kinase, which is implicated in hematologic malignancies. This compound also exhibits off-target effects by inhibiting serine/threonine kinase haspin, a critical regulator of mitotic signaling. FLT3-IN-38 is suitable for cancer research applications, particularly in studies focused on the treatment of FLT3-mutated leukemias. -
IGF2BP1 Inhibitor
IGF2BP1-IN-1 is a selective inhibitor of the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1). It demonstrates potent inhibition of IGF2BP1 with a dissociation constant (KD) of 2.88 nM and effectively suppresses cancer cell proliferation, exhibiting IC50 values of 9 nM in A549 cells and 34 nM in HCT116 cells. Additionally, IGF2BP1-IN-1 induces apoptosis in cancer cells and has been shown to inhibit tumor growth in A549 xenograft mouse models, making it a valuable tool for cancer research and therapeutic development targeting IGF2BP1-mediated pathways. -
IGF2BP3 Inhibitor
IGF2BP3-IN-1 is an inhibitor of IGF2BP3, a RNA-binding protein essential for regulating various cellular processes. With an IC50 value greater than 50 μM, this compound is primarily utilized in cancer research to explore the role of IGF2BP3 in tumor growth and progression. Its application extends to studies investigating the influence of RNA binding proteins on gene expression and potential therapeutic pathways in oncology. -
ALK Tyrosine Kinase Inhibitor
Ceritinib-d7 is a deuterium-labeled derivative of Ceritinib, which functions as a selective and ATP-competitive inhibitor of the ALK (anaplastic lymphoma kinase) tyrosine kinase. This compound is utilized in research to explore mechanisms of ALK-mediated oncogenesis and to evaluate the therapeutic efficacy of targeted treatments in malignancies such as non-small cell lung cancer. Its deuterium labeling allows for advanced studies in pharmacokinetics and metabolism, making it a valuable tool for chemical biology investigations. -
IGF-1R Inhibitor
NVP-AEW541 dihydrochloride is a potent inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), exhibiting an IC50 value of 0.15 μM. This compound also demonstrates inhibition of the insulin receptor (InsR) with an IC50 value of 0.14 μM. NVP-AEW541 dihydrochloride is recognized for its antitumor activity, making it a valuable tool for cancer research and therapeutic investigations targeting IGF signaling pathways. -
ALK Inhibitor
ALK-IN-24 is a potent, orally active inhibitor of anaplastic lymphoma kinase (ALK) with an IC50 value of 1.7 nM, also exhibiting inhibition of insulin receptor kinase with an IC50 value of 6 nM. It effectively suppresses the proliferation of lung adenocarcinoma cells and has demonstrated the ability to inhibit ALK-driven tumor growth in xenograft mouse models. This compound is applicable for research focused on non-small cell lung cancer and other ALK-related malignancies. -
Insulinotropic Polypeptide
Gastric Inhibitory Polypeptide (1-30), porcine is an insulinotropic polypeptide that enhances the secretion of insulin and somatostatin. This truncated form, missing the C-terminal 12 amino acids of the natural GIP, maintains key biological activity, making it valuable for research in glucose metabolism and endocrine function. It is particularly useful in studies examining the role of incretin hormones in insulin regulation. -
IGF-1R/InsR Inhibitor
AZD9362 is a reversible, ATP-competitive inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR). It exhibits potent biological activity with an IC50 of 14 nM for IGF-1R inhibition, making it suitable for cancer research applications. This compound has been shown to enhance the anti-tumor efficacy of AZD5363, presenting significant potential in the study of various cancers, including breast cancer. -
ALK/IR/VEGFR2/TIE2/DLK Inhibitor
CEP-14083 is an ATP-competitive inhibitor targeting ALK, with IC50 values of 2 nM in enzymatic assays. This compound also inhibits other kinases, including the insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2), and dual leucine zipper kinase (DLK). CEP-14083 has been shown to suppress CD274 mRNA expression and the function of NPM/ALK in NPM/ALK-positive T cell lymphoma cells. It is a valuable tool for research focused on lymphoma and related signaling pathways. -
PLK4 Inhibitor
CZS-241 is a selective Polo-like Kinase 4 (PLK4) inhibitor, exhibiting an IC50 of 2.6 nM. In addition to its primary activity, CZS-241 also inhibits TRKA with an IC50 of 2.74 μM. This compound induces apoptosis and effectively arrests the cell cycle at the S/G2 phase. CZS-241 demonstrates potent antiproliferative effects against leukemia cell lines while maintaining safety profiles in normal cell lines, making it a valuable tool for cancer research.
